The Board of Directors of MMFSL ( Board ), has inter-alia superseded the Right issue approval granted on 13th February 2025 and via a fresh resolution approved fund raise by way of offer and issuance of fully paid-up equity shares of the Company for an amount not exceeding Rs. 3,000 Crore; to pursue the proposed Right Issue under SEBI (ICDR) (Amendment) Regulations, 2025 dated 3rd March 2025 ( new simplified regulations ) which have considerably simplified the Rights issue process thereby making it time, process and cost efficient.This is to clarify that the resolution approved today by the Board is not for any additional offer and issuance of Equity Shares but only a fresh approval for the same matter which was announced on 13th February 2025 for the reasons as stated above
M&MFIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Midcap 150 and 0.3 pts more than its Non Banking Financial Company (NBFC) peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Mahindra & Mahindra Financial Services Limited (MMFSL) on 2nd May 2025 superseded its earlier Rights Issue approval from 13th February 2025 and passed a fresh resolution to raise up to Rs. 3,000 Crore through a Rights Issue to eligible shareholders. The fresh approval is taken to avail benefits of SEBI's new simplified Rights Issue regulations notified on 3rd March 2025, which make the process faster and cheaper. No additional shares are being issued beyond the originally planned Rs. 3,000 Crore size. The funds will be used to strengthen capital adequacy and support growth in Assets Under Management (AUM), with the capital raise expected to enhance Tier 1 capital by over 200 basis points. Issue price, entitlement ratio and record date are yet to be decided by the Board or the Rights Issue Committee.
For existing shareholders, this is essentially a re-approval of the same Rs. 3,000 Crore rights issue previously announced, with no change in issue size. The capital infusion should support future growth and strengthen the balance sheet, but shareholders may need to commit additional funds once pricing and ratio are announced.